LIFECORE BIOMEDICAL, INC. Lease Obligation Incurred
LIFECORE BIOMEDICAL, INC. (LFCR) reported Lease Obligation Incurred of $3.91 million for the 12-month period ending 2016-05-29, per its 10-K filed 2018-08-09.
Discontinued › Cash Flow › Other Cash Flow Items
us-gaap:CapitalLeaseObligationsIncurred · last filed 2018-08-09
- LIFECORE BIOMEDICAL, INC. lease obligation incurred for the quarter ending 2016-05-29 was $133.00K.
- LIFECORE BIOMEDICAL, INC. lease obligation incurred for fiscal 2016 was $3.91M.
| Period end | Lease Obligation Incurred 3 month | Lease Obligation Incurred 9 month | Lease Obligation Incurred 12 month |
|---|---|---|---|
| 2016-05-29 | $133.00K derived: 10-K 12 month − 10-Q 9 month · filed 2018-08-09 | $3.91M 10-K · filed 2018-08-09 | |
| 2016-02-28 | $3.77M 10-Q · filed 2017-04-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Annexon, Inc. (ANNX) | United States | $0.147B | -4.22 |
| Corbus Pharmaceuticals Holdings, Inc. (CRBP) | United States | $0.144B | -1.72 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| SPRUCE BIOSCIENCES, INC. (SPRB) | United States | $0.142B | -2.89 |
| Korro Bio, Inc. (KRRO) | United States | $0.141B | -1.81 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Atrium Therapeutics, Inc. (RNA) | United States | $0.140B |